Malaysia and Indonesia , home to more than 310 million people with a fast-growing need for mental health care, form the initial focus of an initiative combining neuroscience devices, professional education and AI-supported mental healthcare PLEASANTON, Calif. , Oct. 26, 2026 /PRNewswire/ -- Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions for healthcare and life sciences, today announced the launch of Neurotechnology AI Devices Sales and Solutions through its wholly owned subsidiary, Quantum Nexis Inc. ("Quantum Nexis"), with strategic healthcare, wellness, neuroscience and public-sector initiatives being actively pursued across Southeast Asia . As healthcare systems shift toward preventive care, mental resilience, longevity, cognitive performance and wellness outcomes, Quantum Nexis is building a strategic foundation to bring advanced brain mapping and neurotechnology capabilities to healthcare organisations, wellness centres, hospitality groups, enterprises and government-aligned initiatives throughout Malaysia and Indonesia . The solutions bring together neurotechnology, neuropsychology, psychotherapy and AI through program encompassing device manufacturing development, clinical technology integration and professional education. The aim is to help practitioners translate advances in brain science into responsible, practical applications for mental health treatment, rehabilitation and cognitive wellbeing. Key Highlights Large, fast-growing market: Malaysia and Indonesia are home to more than 310 million people. Asia-Pacific is the fastest-growing region for mental health technology, with a projected 13.2% annual growth rate from 2024 to 2030 (Ariston). Three revenue streams: Neurotechnology device sales and servicing; professional training and certification through a Quantum Nexis academy; and recurring AI-enabled software subscriptions for clinics. Builds on HCTI's core strengths: HCTI's existing cloud, data and AI capabilities power the clinical software layer. Local manufacturing base: Phased device integration and assembly in Malaysia , whose medical device exports grew 31% to RM37 billion in 2024. Near-term milestones: First regulatory submission to Malaysia's Medical Device Authority Q1 2027; first locally assembled devices Q3 2027. The market opportunity Demand for brain-health technology is accelerating worldwide. The global neurotech devices market is projected to grow from US$15.2 billion in 2024 to US$30.3 billion by 2030, a compound annual growth rate of 12.2% (Market Glass). Within mental health technology, Asia-Pacific is the fastest-growing region, at a projected 13.2% a year through 2030 (Ariston). In the initiative's two launch markets, the need is pressing and the gap in care is wide: Malaysia : around one million people aged over 15, or 4.6% of that population, live with depression, double the number recorded in 2019, according to the Ministry of Health's National Health and Morbidity Survey (NHMS) 2023. The same survey found that about one in six children is likely to experience mental health problems. Indonesia : only 10.4% of young people aged 15 to 24 with depression seek treatment, according to the Ministry of Health's 2023 Indonesian Health Survey (SKI). The Ministry ranks mental health problems as the second-largest cause of years lived with disability in the country. Together, these figures point to a large population that would benefit from better assessment, earlier intervention and more personalised care, and to the need for more professionals trained to deliver it. "Making neurotechnology accessible requires more than supplying equipment. Professionals need the knowledge to interpret the information, select appropriate interventions and understand the limits of each technology," said Ehsan Masoumi , Director, Quantum Nexis. "Our vision is to develop regional capability across devices, software, education and clinical practice, so that advances in neuroscience can contribute meaningfully to people's mental health and everyday functioning." Building regional technology and manufacturing capability The development roadmap includes EEG and quantitative EEG (qEEG) tools for recording and analysing brain electrical activity; neurofeedback and physiological biofeedback systems; and non-invasive brain stimulation technologies, including transcranial electrical stimulation and repetitive transcranial magnetic stimulation (rTMS). A core strategic objective is to develop manufacturing capability in Malaysia through a phased pathway covering device integration, assembly, software configuration, testing, calibration, quality assurance and technical support. Manufacturing and market introduction will progress in accordance with technical agreements, quality requirements and applicable regulatory authorisations. Connecting neuroscience with artificial intelligence AI development will focus on helping professionals organise and